Item 1.02. Termination of a Material Definitive Agreement.

On September 23, 2022, Incyte Corporation notified Calithera Biosciences, Inc., of its intent to terminate for convenience that certain Collaboration and License Agreement, by and between Incyte and Calithera Biosciences, dated January 27, 2017, or the Collaboration and License Agreement. The termination will be effective on or about December 28, 2022. No material early termination penalties will be payable by either party.

The Collaboration and License Agreement is filed as exhibit 10.1 to our Quarterly Report on Form 10-Q, for the three months ended March 31, 2017 (File No. 001-36644), filed with the Securities and Exchange Commission on May 9, 2017. For a summary of the material terms of the Collaboration and License Agreement please see " Part I, Item 1. Business - Partnered Programs - Arginase Inhibitor INCB001158 for Oncology " of our Annual Report on Form 10-K for the year ended December 31, 2021 (File No. 001-36644), filed with the Securities and Exchange Commission on March 31, 2022, which summary is incorporated herein.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses